CD19 and neoplasm: Although excellent anti-tumor activity has often observed with these macromolecular adapters, no studies aimed at controlling a CAR T cell derived toxicity were ever reported except a comment by Ma et al.36 that administration of an initial low dose of FITC-anti-CD19 adapter followed by a higher dose of the same adapter caused less toxicity than two consecutive administrations at the higher adapter dose.